Fundraising FoxAgent Capital — 2024 Investments
2 investments dated 2024 · listed companies and verified rows first · show all
Hinge Bio is a biotechnology company developing next-generation therapeutics based on its GEM-DIMER platform, aimed at improving efficacy and reducing resistance and side effects.
BiotechHealthtechBurlingame, US
Daniel J. Capon(Director)Carin Mueller Rollins(Co-Founder & Chief Operating Officer)Harold E. Selick, PhD(Executive Officer, Director)Miriam Siekevitz(Executive Officer)inHarold E. "Barry" Selick(Chief Executive Officer & Director)Paul Brunetta(Chief Medical Officer)in
Co-investorsPoint72Baruch Future VenturesInVivium CapitalRidgeback Capital
Primrose Bio develops high-efficiency production systems for innovative and complex biologics, using advanced protein expression and enzyme engineering technologies deployed across commercially proven platforms.
BiotechDeep TechMedical DevicesSan Diego, US
Helge Zieler(Director, Executive Officer)inDrew Burch(Chief Executive Officer)Diane Retallack, PhD(President & Chief Operating Officer)
BoardJ. Todd Mitchell(Director)Matthew Korenberg(Director)Matthew Reber(Director)
Co-investors1315 Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.